Skip to main content

Table 2 Correlation of PIK3CA mutation status with the clinicopathological characteristics of breast cancer

From: Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer

Clinicopathological parameters Mutated (%) Wild type (%) P
All Tumor Cases 64 (34.4) 122 (65.6) NS
Histological Type    NS
Ductal/Other Carcinoma 53 (32.5) 110 (67.5)
Lobular Carcinoma 11 (47.8) 12 (52.2)
Tumor Stage    NS
T1 13 (30.2) 28 (65.1)
T2 37 (34.9) 69 (65.1)
T3 9 (42.9) 12 (57.1)
T4 5 (41.7) 7 (58.3)
Node Status    0.042
N0 25 (27.8) 65 (72.2)
N+ 37 (42.5) 50 (57.5)
Tumor Grade    <0.001
G1 16 (80.0) 4 (20.0)
G2 35 (36.5) 61 (63.5)
G3 13 (18.8) 56 (81.2)
Hormone Receptor Status    0.002
HR+ 58 (40.3) 86 (59.7)
HR- 6 (14.3) 36 (85.7)
HER2 Status    0.032
HER2+ 3 (13.6) 19 (86.4)
HER2- 61 (37.2) 103 (62.8)
Age    NS
<50 years 6 (26.1) 17 (73.9)
>50 years 58 (35.6) 105 (64.4)
Molecular Type    0.003
HR+/HER2- 57 (42.5) 77 (57.5)
HR+/HER2+ 1 (10.0) 9 (90.0)
HR-/HER2+ 2 (16.7) 10 (83.3)  
HR-/HER2- 4 (13.3) 26 (86.7)
  1. The mutation frequency, as determined by NGS, decreased with increasing tumor grade: 85 % for G1, 37 % for G2, and 20 % for G3. PIK3CA mutations were more frequently detected (42 %) in HR+ breast cancer than in HR- breast cancer (14 %). PIK3CA mutations were more frequently detected in HER2- breast cancer (38 %) than in HER2+ breast cancer (14 %)